Compare HNRG & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNRG | EVO |
|---|---|---|
| Founded | 1949 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.0M | 934.1M |
| IPO Year | 1995 | N/A |
| Metric | HNRG | EVO |
|---|---|---|
| Price | $15.18 | $3.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $25.38 | $7.00 |
| AVG Volume (30 Days) | ★ 931.4K | 74.4K |
| Earning Date | 05-11-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 116.78 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $469,466,000.00 | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $12.12 | $10.05 |
| P/E Ratio | $16.41 | ★ N/A |
| Revenue Growth | ★ 16.09 | N/A |
| 52 Week Low | $13.60 | $2.31 |
| 52 Week High | $24.70 | $4.80 |
| Indicator | HNRG | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 40.47 | 63.79 |
| Support Level | $15.02 | $2.87 |
| Resistance Level | $21.07 | $3.78 |
| Average True Range (ATR) | 0.85 | 0.09 |
| MACD | 0.06 | 0.10 |
| Stochastic Oscillator | 22.02 | 78.38 |
Hallador Energy Co is a vertically integrated, independent power producer (IPP) and fuel company with operations in Indiana. The Company operates across multiple stages of the energy value chain, from accredited capacity and energy to coal. The Company's electric operations are located within the Midcontinent Independent System Operator's (MISO) footprint. The company's business is organized based on the services and products it provide in two segments: (i) Electric Operations and (ii) Coal Operations.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.